Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Verastem ( (VSTM) ) has shared an announcement.
On May 7, 2026, Verastem posted an updated corporate presentation outlining its strategy around AVMAPKI FAKZYNJA co-pack for KRAS mutant recurrent low-grade serous ovarian cancer and a broader pipeline of RAS/MAPK pathway-targeted programs. The materials emphasize ongoing and planned clinical trials, collaborations such as its VS-7375 partnership with GenFleet Therapeutics, and the use of non-GAAP operating expense metrics to help investors assess operating performance and market opportunities amid substantial development, regulatory, and commercialization risks.
The presentation underscores Verastem’s dependence on successful execution of Phase 1–3 trials, regulatory interactions, and commercialization efforts for AVMAPKI FAKZYNJA co-pack in the U.S., as well as on maintaining key partnerships and adequate financing. It also details numerous uncertainties facing the business, including clinical trial enrollment and safety outcomes, reimbursement and healthcare policy shifts, competition in oncology, supply and manufacturing reliability, and the potential for smaller-than-expected addressable markets for its drug candidates.
The most recent analyst rating on (VSTM) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
The score is held back primarily by weak financial quality—large losses, worsening cash burn, and meaningful leverage—despite improving revenue and a repaired equity position. Technicals add downside pressure with the stock below all key moving averages and negative MACD, while the earnings call provides a partial offset due to strong early launch execution, defined milestones, and runway into H1 2027. Valuation is not supportive given negative earnings and no dividend.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem, Inc., which operates as Verastem Oncology, is a biotechnology company focused on developing and commercializing novel targeted therapies for cancers driven by the RAS/MAPK pathway. Its lead offering is the AVMAPKI FAKZYNJA co-pack, combining avutometinib capsules and defactinib tablets, aimed at treating adult patients with KRAS mutant recurrent low-grade serous ovarian cancer and expanding into broader oncology indications.
Average Trading Volume: 1,921,968
Technical Sentiment Signal: Sell
Current Market Cap: $527.9M
Learn more about VSTM stock on TipRanks’ Stock Analysis page.